Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

INTRODUCTION: Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) with a single infusion site. The efficacy and safety of foslevodopa/foscarbidop...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldred, Jason, Freire-Alvarez, Eric, Amelin, Alexander V., Antonini, Angelo, Bergmans, Bruno, Bergquist, Filip, Bouchard, Manon, Budur, Kumar, Carroll, Camille, Chaudhuri, K. Ray, Criswell, Susan R., Danielsen, Erik H., Gandor, Florin, Jia, Jia, Kimber, Thomas E., Mochizuki, Hideki, Robieson, Weining Z., Spiegel, Amy M., Standaert, David G., Talapala, Saritha, Facheris, Maurizio F., Fung, Victor S. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630297/
https://www.ncbi.nlm.nih.gov/pubmed/37632656
http://dx.doi.org/10.1007/s40120-023-00533-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630297/
https://www.ncbi.nlm.nih.gov/pubmed/37632656
http://dx.doi.org/10.1007/s40120-023-00533-1

Ejemplares similares